ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1778

Adenosine A2A Receptor (A2AR) Activation Stimulates Increased Expression of Collagen-1 and Collagen-3 by Different Signaling Pathways in Normal Human Dermal Fibroblasts

Miguel Perez Aso1 and Bruce N. Cronstein2, 1NYU Univ Medical Center, New York, NY, 2Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adenosine receptors, Collagen, fibroblasts and signal transduction

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cell-cell Adhesion, Cell Trafficking and Angiogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Pathological fibrosis in the skin and other organs is the hallmark of scleroderma and other fibrosing diseases.  Adenosine, acting at A2AR, plays a critical role in wound healing and fibrosis of the skin and previous studies have demonstrated that blockade or deletion of A2A receptors prevents dermal fibrosis in response to bleomycin, a murine model of scleroderma.  Moreover, A2AR blockade enhances the strength of scars by, in part, diminishing the collagen 3 (Col3) content of the scar relative to Col1 content.  Here we determined whether expression of Collagen-1 (Col1) and Col3 proceed by different signaling pathways.

Methods: Col1 and Col3 expression were determined by Western-Blot analysis of normal human dermal fibroblasts (NHDF). 

Results: Surprisingly the concentrations of the A2AR agonist CGS21680 required to increase Col1 expression were significantly lower than those required to increase Col3 (0.1µM: 147±6% for Col1 [p<0.01, n=23] vs 1µM: 155±16% for Col3, [p<0.01, n=18) although increases in both were completely blocked by the A2AR-antagonist SCH58261 (0.1µM). The selective Protein kinase A (PKA) activator 8-Cl-cAMP markedly increased Col1 expression (0.1µM: 280±74% [p<0.01, n=3), but inhibited Col3 expression by as much as 68±11% (p<0.01, n=4). PKA inhibition by PKAi prevented the CGS21680-stimulated increase in Col1 but elicited an increase of Col3 at lower concentrations than in the absence of PKAi (0.1µM, 110±10% versus 182±30% [p<0.05, n=4). In contrast, stimulation with the specific Epac activator 8-CPT-2’-O-Me-cAMP did not affect Col1, but increased Col3 production  by 362±85% (p<0.05, n=3). Inhibition of AKT, erk, p38 and JNK with LY294002 (10µM), U0126 (1µM), SB203580 (1µM) and SP600125 (20µM), respectively, demonstrated that increased expression of Col1 and Col3 depend on AKT and p38. However, CGS21680 0.1µM increased Col3 only upon ERK or JNK blockade, an effect similar to PKA inhibition. 

Conclusion: Our work strongly suggests that at nanomolar concentrations of CGS21680 PKA activity prevails over Epac, thereby activating Col1 expression and inhibiting Col3 but in the mmolar range, the PKA/ERK/JNK inhibition of Col3 is overcome by activation of Epac/p38 and Pi3K/AKT. These observations may explain the dramatic decrease of the Col1/Col3 ratio in hypertrophic and immature scars, where adenosine is present in µmolar ranges, when compared to normal skin, where adenosine concentration varies from 30 to 300nM.


Disclosure:

M. Perez Aso,
None;

B. N. Cronstein,

Canfite BioPharma,

1,

NIH, URL Pharma, OSI,

2,

Bristol-Myers Squibb, Novartis, URL, Regeneron, Gismo Therapeutics,

5,

Arthritis Foundation, SLE Foundation,

6,

Patents on use of adenosine receptor antagonists to treat or prevent fibrosis. Multiple other patents.,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-a2a-receptor-a2ar-activation-stimulates-increased-expression-of-collagen-1-and-collagen-3-by-different-signaling-pathways-in-normal-human-dermal-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology